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Abstract – 249 words: 27 
Purpose: Dengue virus is the most frequent arthropod-borne viral infection worldwide. 28 
Simultaneously to the growth of its incidence, cases of bacterial coinfection in dengue have been 29 
increasingly reported. The clinical course of dual infections may worsen for reciprocal interactions 30 
and delays in the diagnosis, so that clinicians should be aware of this eventuality. Therefore, we 31 
reviewed literature to provide an overview of the epidemiological, clinical and physiopathological 32 
issues related to bacterial coinfections and bacteremia in dengue. 33 
Methods: Clinical studies and case reports regarding bacteremia and bacterial coinfections in 34 
dengue and the interactions between the pathogens published on PubMed were reviewed. 35 
Results: We found 26 case reports, only 3 studies on concurrent bacteremia and 12 studies 36 
reporting data on bacterial coinfections in dengue. According to the three available studies, the 37 
0.18-7% of dengue infections are accompanied by concurrent bacteremia, while the 14.3-44.4% of 38 
dengue-related deaths seems associated to bacterial coinfections. Comorbidities, advanced age and 39 
more severe dengue manifestations could be risk factors for dual infections. A longer duration of 40 
fever and alterations in laboratory parameters such as procalcitonin, hyponatremia, leukocyte count 41 
and renal function tests can raise the suspicion. 42 
Conclusions: Despite the real burden and consequences of this emerging concern is still not 43 
computable accurately due to the lack of a significant number of studies on large cohorts, clinicians 44 
need a greater awareness about it to early recognize warning signs, to properly use available 45 
diagnostic tools and to readily start antibiotic treatment able to prevent worsening in mortality and 46 
morbidity. 47 
KeyWords: Dengue; Bacteremia; Coinfection; Bacteria; Innate Immunity; Pathogenesis. 48 
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Manuscript – 25.940 characters (including spaces): 74 
Introduction 75 
Dengue virus (DEV) infection is the most frequent arthropod-borne viral disease worldwide, 76 
transmitted mainly by Aedes spp mosquitoes and caused by one of four different serotypes 77 
belonging to the Flaviviridae family together with West Nile virus and many others. The global 78 
burden of DEV has grown dramatically in the last decades and one recent estimate reports 390 79 
million of DEV infections per year, of which 96 million clinically manifesting [1]. The clinical 80 
presentation of dengue can range from asymptomatic infections to serious life-threatening 81 
manifestations such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [2]. 82 
The severity of the infection depends on a large number of factors related to the virus and to the 83 
host. Moreover, two sequential infections by different serotypes of DEV can predispose to DHF and 84 
DSS due to an antibody-dependent enhancement of DEV infection which leads to the generation of 85 
a large amount of infected cells [2]. In developed countries the disease is currently sporadic and 86 
occurs mainly in travellers, especially those returning from Southeast Asia [3]. It has been estimated 87 
that about 2% of all diseases among travellers returning from endemic regions it is caused by DEV 88 
[3], but more surveillance data are required to assess the real burden of the disease, especially 89 
nowadays considering the increase in intercontinental travels and globalization.  90 
There are different reports in literature regarding dual infections with DEV and bacteria such as 91 
Leptospira spp, Staphylococcus spp and Enterobacteriaceae [4-6]. Depending on the studies and on 92 
the severity of dengue, it seems that from 0.18% to 7% of DEV infections are associated with 93 
concurrent bacteremia (CB) [7-9]. Although the overall proportion of dual infections may be small, 94 
the absolute number can become awesome considering the above data, especially during major 95 
DEV outbreaks. Moreover, the clinical course of dual infections may worsen for dangerous 96 
interactions between pathogens, for missed diagnosis due to unusual clinical presentations and for 97 
delays in the beginning of the most appropriate therapy, so that clinicians should be aware of this 98 
eventuality. It is not clear yet whether and how DEV can predispose to super-infection and to 99 
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bacteremia. Different hypothesized mechanisms are the induced weakened immunity, the severe 100 
neutropenia and the microbial translocation observed during the disease [10-12]. On the other hand, 101 
also bacterial infections may increase susceptibility to DEV [13]. To date there is a dearth of studies 102 
on this issue, but what seems rational is that concurrent bacterial infections can not always be a 103 
mere coincidence. Herein we review the literature about CB and bacterial coinfections in dengue to 104 
evaluate the burden of the phenomenon and the possible pathophysiological mechanisms that can 105 
explain it and to point out the issues and the limits in managing and in recognition of dual 106 
infections. 107 
Materials and Methods 108 
A PubMed search from January 1943, when Kimura and Hotta first isolated DEV, through March 109 
2016 was performed to identify case reports and studies addressing the bacterial coinfection and CB 110 
issue in DEV infection. We made our search combining bacteremia, coinfection, 111 
immunosuppression, innate immunity, case reports and bacteria with dengue as Mesh terms and 112 
concurrent bacteremia, microbial translocation, case report and dual infection with dengue as 113 
keywords. We considered all case reports with at least an english written abstract. For case reports 114 
of which we were not able to read more than the abstract we reported the missing data as not 115 
available. Conversely, we considered only english written published or accepted manuscripts of 116 
studies on adults and with a bacterial coinfection diagnosis made on the basis of culture tests, 117 
considering serological diagnosis of bacterial coinfections unreliable due to cross-reactivity issues, 118 
as explained further below. The search was augmented by review of bibliographic references from 119 
the included studies and case reports to identify additional relevant papers.  120 
Since it is epidemiologically and clinically fundamental to differentiate DEV cases with CB from 121 
those with bacterial coinfections without bacteremia or with a positive blood culture collected 122 
without stringent temporal limits with respect to dengue diagnosis, data reported by studies that 123 
isolated bacteria from blood within a maximum of 72 hours of patient’s admission for dengue were 124 
considered as data concerning CB, whilst all the studies in which the previous timeframe for blood 125 
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culture samples collection is missing or exceeded were considered as studies on bacterial 126 
coinfections (BC) in dengue. Therefore, BC include also dual infections without bacteremia, 127 
infective complications of dengue and nosocomial infections.  128 
Results 129 
We found 26 case reports, 3 studies specifically focused on CB [7-9] and 12 studies [7-9, 11, 14-21] 130 
reporting data on CB or BC in DEV disease fulfilling the inclusion criteria. We then summarized 131 
the evidences to performe a review of the literature providing an overview of the epidemiological, 132 
clinical and physiopathological issues related to BC and CB in DEV infection. 133 
Epidemiological Issues 134 
Only three studies have been addressed to investigate on the CB issue in dengue and they were all 135 
retrospective [7-9]. The main characteristics of these studies and of the enrolled populations are 136 
summarized in Table 1. The reported CB rates were 0.18% [7], 1.2% [8] and 7% [9]. The first two 137 
studies also reported BC rates of 0.3% [7] and 4% [8], which are almost twice and more than triple 138 
the CB rates in the same cohorts respectively. Two out of the three studies were conducted on 139 
patients presenting a positive laboratory confirmation of DEV infection [7, 8], while Lee et al. 140 
evaluated CB in patients affected by DHF or DSS only [9]. This difference may explain the 141 
significant gap between the rate they found and those reported by the other two studies. In 142 
agreement with the hypothesis that CB and BC rates increase with the increasing severity of DEV 143 
infection, as corollary of their main objective, a few studies on smaller cohorts addressing risk 144 
factors and outcomes exclusively for DHF reported CB rates similar to those reported by Lee, 145 
precisely 7% [14], 7.3% [15] and 8.1% [16].  Solely one out of the three studies on CB in dengue, 146 
by Thein et al. [7], has specified that only patients with clinical deterioration despite treatment for 147 
DEV were tested with blood cultures, whilst in the other two studies it is not stated whether all the 148 
included patients underwent a blood sample collection for bacterial cultures [8, 9]. Therefore, in 149 
addition to the limitations related to the retrospective design, it is also possible that some of the dual 150 
infection cases were not diagnosed and that the reported rates underestimate the real amount of CB 151 
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in dengue. To date, only one prospective study has been conducted on bacteremia in dengue, but its 152 
aim was not to evaluate CB rates [17]. They examined secondary bacteremia rates in DEV-infected 153 
adults with a duration of fever superior to the usual 5 days [17]. They reported a 25% of secondary 154 
bacteremia in a small cohort of 40 patients, without providing the timeframe for blood cultures 155 
collection and they concluded that an average longer duration of fever respect to the usual lenght of 156 
dengue fever could be a warning sign of BC [17]. Actually, considering DEV-infected cohorts 157 
selected for specific features, such as the duration of fever or the most severe manifestations of 158 
dengue, CB and BC rates may increase, identifying categories of patients at greater risk of dual 159 
infections. More specifically, from 26.5% to 45.4% of cases admitted to an intensive care unit for 160 
dengue can develop BC [18, 19] and 22.7% of all the admitted cases requires treatment for septic 161 
shock [19]. Furthermore, up to 17.4% of elderly patients, i.e. patients with 65 years or more, 162 
presenting with DHF may experience CB [15] and the 42.8% of DHF cases who develops acute 163 
renal failure has also CB [16]. These data reinforce the hypothesis that CB and BC rates may 164 
increase with increasing severity of dengue and that certain categories such as the elderly, the 165 
patients requiring intensive care or those developing organ dysfunction could be at greater risk of 166 
dual infection during dengue. 167 
Among the most frequently isolated bacteria responsible for CB in dengue, as shown in Table 1, 168 
there are Staphylococcus aureus, Escherichia coli, Klebsiella spp, Salmonella spp and 169 
Streptococcus spp, while rarely reported are Pseudomonas aeruginosa, Moraxellaceae, 170 
Enterococcaceae and Aeromonas spp [7-9]. It is interesting to note that a substantial portion of 171 
these bacteria are capable of colonizing parts of human body and that when the source of bacterial 172 
infection was investigated, no organ localization with primary bacteremia was found to be the most 173 
frequent condition. In Table 2 we listed all dual infection case reports found in literature. In case 174 
reports a different set of bacteria prevails; the majority of them does not usually colonize human 175 
body and it is characterized by peculiar modes of transmission, such as Mycoplasma pneumoniae or 176 
Orientia tsutsugamushi. The difference between the bacterial isolates reported by the previous 177 
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studies and those reported by case reports may be due at least in part to publication bias and to our 178 
inclusion criteria, which are not the same for the two types of scientific report. 179 
Although the available reports show that a significant portion of DEV infections could be associated 180 
to a bacterial infection, to date there are too few studies on CB and BC in DEV disease to define 181 
with certainty the real burden of this emerging concern. Besides, to our knowledge, prospective 182 
studies on large sample size of patients are missing and they would help to define more confidently 183 
the CB and BC rates in dengue. The available data are also difficult to compare and to analyze 184 
together due to the lack of uniformity with which the studies have been conducted and it should be 185 
pointed out that all the available informations related to this issue were obtained from cohorts with 186 
special features of settings in tropical and subtropical regions [7-9, 14-19] and this may be a 187 
limitation to the use of all these data in Western clinicians reality.We need local, national and 188 
international surveillance systems for CB and BC in DEV disease and a shared systematic approach 189 
to the analysis of the phenomenon. Moreover, we need studies on large cohorts with different 190 
features than of those carried out so far, for example studies with a prospective design and with the 191 
aim of evaluating the dual infection issue among migrants and travellers in Western countries too. 192 
Clinical Issues 193 
DEV infection fatality rate ranges from 0.5% to 5% and though it may increase twentyfold when 194 
DHF and DSS develop, DHF and DSS cases alone account for less than 50% of all DEV-related 195 
deaths [14]. Regarding dengue mortality due to CB or BC, the available data are scarce, are 196 
provided by a few studies on small cohorts, with just 8-28 fatal cases and a large variability in the 197 
reported rates, however, to date what they show is that from 14.3% to 44.4% of DEV-related deaths 198 
could be associated to bacterial coinfections [14, 19-21] and that an increased leucocyte count and 199 
cell band percentage have been associated with a higher risk of CB and BC and of death in DEV 200 
infected patients [14, 19]. If further studies on larger cohorts would confirm the previous rates, the 201 
dual infection issue would be certainly not of secondary importance in the management of DEV 202 
disease, starting as early as from the triage of patients.  203 
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A first problem in recognizing dual infections in DEV cases is the perfect overlap of the clinical and 204 
laboratory presentation between DEV disease and some of the others infections with which it may 205 
present in association. As it is known, most if not all of the signs and symptoms found in DEV 206 
disease are not specific [2]. Considering typhoid fever (TF), as example, the diarrhea, the 207 
gastrointestinal bleeds, the singular pattern of increase in transaminases for which AST level rises 208 
more quickly and reachs a higher value than ALT and then reverts to normality first, the leukopenia 209 
with neutropenia, the thrombocytopenia and even the relative bradycardia may all be found also in 210 
DEV infection [2, 22-24].  211 
Few studies have attempted to describe how DEV clinical presentation changes in conjunction with 212 
bacterial infections and what are the risk factors for CB. The first study was conducted by Lee et al. 213 
[9] on adults with DHF and DSS only. Patients with dual infections were older, with a longer 214 
lasting fever (an average of 8 vs 4 days) and with higher frequencies of DSS, acute renal failure, 215 
gastrointestinal bleed, altered consciousness, unusual DEV manifestations and mortality [9]. Acute 216 
renal failure and a fever lasting for more than 5 days were found to be independent risk factors for 217 
CB [9]. These conclusions agree with the previously reported studies on DEV-infected patients with 218 
a long lasting fever or developing acute renal failure, in whom dual infection rates were higher 219 
compared to those found in patients without these complications [16, 17].  220 
See et al. found that patients with DEV and CB were more likely to have several comorbidities, in 221 
particular diabetes mellitus, hypertension, hyperlipidemia, chronic renal failure and cancer and that 222 
they have a higher hospital mortality [8]. Besides, they created and validated a Dengue Dual 223 
Infection Score (DDIS) for early identification of DEV infected patients in need of empirical 224 
antibiotic treatment [8]. The DDIS can range from 0 to 5 and it is obtained from the attribution of 225 
one point for each of the following parameters if present within 24 hours from admission: pulse rate 226 
≥ 90 beats/min, total white cell count ≥ 6.000/µL, hematocrit < 40%, sodium < 135 mmol/L and 227 
urea ≥ 5 mmol/L [8]; a DDIS ≥ 4 was found to be associated to CB in 94.4% of cases [8]. It is 228 
interesting to note that the same cut-off of 6.000 white blood cells has been associated with a higher 229 
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risk of BC and with a risk of death increased by almost 10 times [19]. Moreover, studies on severe 230 
DEV infections identified in the increased leukocyte and cell band count a significant warning sign 231 
of serious dengue, sugesting the possibility of a superimposing bacterial infection [14, 19]. Lastly, 232 
Thein et al. compared CB cases with only DEV-infected cases and found that at admission dual 233 
infected patients have higher mean temperatures (38.4°C vs 37.6°C) and neutrophil count, more 234 
frequently a Pitt Bacteremia Score (PBS) ≥ 4, hematocrit change ≥ 20% and DSS, while they have 235 
lower serum albumin levels, lymphocyte and platelet count and surprisingly lower rates of 236 
hemorrhagic manifestations [7]. DEV-infected patients with CB need also more volume of fluids 237 
for a longer period [7]. They concluded proposing the PBS as a valuable resource to detect early CB 238 
in DEV infections, but not all the dual infections evolve in severe sepsis and even less start so 239 
severely, while PBS only distinguishes between patients critically ill or not [7].  240 
A promising contribution to identify BC and CB among patients with confirmed DEV infection 241 
could come from the use of procalcitonin. Currently only one study investigated on that and it was 242 
carried out on patients admitted to intensive care unit for dengue [18]. The patients with bacteremia 243 
showed significantly higher procalcitonin level than those without, so that they suggested that 244 
procalcitonin assessment could help to exclude bacteremia in DEV cases, considering its high 245 
sensitivity and negative predictive value [18]. 246 
Once the dual infection is suspected, it is fundamental to use the correct diagnostic tools to confirm 247 
the suspicion. Depending on the available DEV serology test, sensitivity and specificity can range 248 
considerably and false positivity for DEV in case of leptospirosis, brucellosis and TF has been 249 
described, probably due to polyclonal activation or cross-reactivity occurrence [25, 26]. Moreover, 250 
it is possible also the contrary. For example, the Widal serodiagnosis used to detect Salmonella 251 
typhi may result falsely positive in patients affected by DEV [27]. As shown in Table 2, a large part 252 
of dual infections is diagnosed by physicians using only DEV serology. Cases considered as 253 
coinfections may actually be a single infection with a false positive serology for one of the two 254 
implicated pathogens and solely a positive bacterial culture associated with a direct diagnostic 255 
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method for DEV, such as PCR or NS1 antigen detection, would give the certainty of the dual 256 
infection.  257 
Physiopathological Issues 258 
DEV pathogenic mechanisms have been investigated in detail, but little is known about the 259 
pathogenesis of BC and CB in dengue. The majority of case reports and studies [4-9, 17] cite as the 260 
possible cause of this clinical concern the vascular leakage and the associated disintegration of the 261 
mucocutaneous barrier described during dengue [5, 12, 28, 29]. Consistent with this hypotesis are 262 
the previously reported data on bacterial isolates from DEV-infected patients which show that a 263 
large portion of the bacteria involved in coinfection are usual colonizing of human body [7-9]. 264 
Considering that one of the main DEV cellular target are monocytes/macrophages and that a large 265 
number of these cells resides in the gut [28], the replication of DEV in them may produce an 266 
inflammatory milieu, where the breakdown of the digestive epithelial barrier occurs [12, 28, 29], 267 
followed by the microbial translocation (MT) of resident bacteria from the enteric lumen into the 268 
bloodstream [12, 28, 29]. The same event has been hypothesized also for Staphylococcal 269 
bacteremia, following disruption of the cutaneous endothelial lining in patients with predisponing 270 
skin comorbidities and dengue [5]. Recent studies reported higher plasma levels of microbial 271 
translocation markers in DEV infected patients compared to healthy controls [28]. It also seems that 272 
MT correlates with DEV infection severity [12, 28]. However, this pathogenic model has yet to be 273 
demonstrated in vivo. If we consider the MT as the only mechanism whereby explaining dual 274 
infections, we should expect a higher incidence of bacterial infections in patients with greater 275 
vascular damage and hemorrhagic signs, but evidences are still conflicting. If CB and BC rates 276 
seem to increase with increasing severity of DEV and coinfected patients seem to develop more 277 
frequently DSS [7], it is also true that lower rates of hemorrhagic manifestations has been noted in 278 
dual infections compared to only DEV-infected controls [7]. Finally, the MT model cannot explain 279 
all bacterial coinfections in dengue. For instance, especially in high-incidence countries for TF, an 280 
undetermined number of chronic carriers of Salmonella typhi could face Salmonella typhi 281 
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bacteremia if infected by DEV through MT, but Salmonella spp and some of the other bacteria 282 
involved in dual infections, such as Leptospira spp, don not usually represent part of the normal 283 
flora of the gut, protagonist of MT. Furthermore, it should be state that some of the reported 284 
coinfections such as those with Leptospirosis spp, Burkholderia pseudomallei, Mycoplasma 285 
pneumoniae or Orientia tsutsugamushi could merely be a co-occurrence by chance of both the 286 
pathogens in the same individual. 287 
Hypothetically, another possible mechanism to explain bacterial coinfections might be the severe 288 
absolute neutropenia, which may develop due to bone marrow suppression induced by DEV [11]. 289 
Despite this hypotesis could be reasonable, in a retroscpecitve study on a large cohort of DEV-290 
infected patients, a neutrophil count ≤ 500 cells/µL was not found to be a predictor of nosocomial 291 
bacterial infections nor it was associated with a more frequent antibiotic use, probably because of 292 
the short and transient duration of the neutropenia [11].  293 
It seems that DEV can cause a transitory immune suppression affecting the immune system cells 294 
during acute infection [10], so much so that during and after the infection immune system is less 295 
effective in mounting a defensive response also against secondary bacterial threats. In fact, DEV 296 
seems able to diminish response to proliferative stimuli in T cell populations by impairing antigen-297 
presenting cells functions [30], to reduce the phaghocitic and migratory skills of splenic and 298 
peritoneal-cavity macrophages [31] and to suppress the interferon signaling pathway through the 299 
down-regulation of different genes [32]. Moreover, in mosquitoes DEV seems capable of increasing 300 
the susceptibility to Staphylococcus aureus and Pseudomonas aeruginosa septic injury [33] and of 301 
down-regulating the expression of different genes involved in the major innate immunity pathways, 302 
including some genes coding for receptors of viral and bacterial pathogen-associated molecular 303 
patterns and for antimicrobial peptides, the production of which was shown to be reduced in 304 
response to bacterial challenges [34]. Considering the notable overlap between the innate immune 305 
system of diptera and human [33, 34], the explanation of bacterial and DEV coinfections may be 306 
found by studies on interactions between DEV and the human innate immune systems. Actually, in 307 
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human myeloid/plasmocytoid dendritic cells and monocytes DEV can affect the expression of some 308 
co-stimulatory molecules and of the Toll-Like Receptors (TLRs), proteins with a pivotal role in the 309 
innate immune system [35]. The modulation of the expression of TLRs may influence not only the 310 
development of a specific immune response against the virus, but also the dendritic cells activation 311 
[35], thereby influencing immune responses involved in antibacterial defenses as well. This effect 312 
seems to depend on the severity of DEV infection [35] and consistent with these findings, the 313 
presence of subneutralizing antibodies induced by previous exposure to a different DEV serotype 314 
has been linked not only to a higher risk of severe form of dengue, but also to a more prominent 315 
down-regulation of TLRs expression and up-regulation of suppressors of the NF-kB signaling 316 
pathway, crucial for cytokine production [36]. Considering these results, the aforementioned higher 317 
CB and BC rates in DHF and DSS cases should not surprise. A summary of the main mechanisms 318 
through which DEV may induce CB and BC is represented in Figure 1.  319 
Finally, if it is possible that DEV can facilitate CB and BC, it is also possible that bacterial 320 
contagion could increase susceptibility to more symptomatic and severe forms of dengue. It has 321 
been described a modulating effect of LPS, the Gram-negative outer membrane endotoxin, on DEV 322 
replication [13]. Chen et al. observed that when LPS was added to in vitro cultures of human 323 
monocytes and macrophages after DEV infection, DEV replication was enhanced and prolonged 324 
[13] and similar conclusions were also reached by one study in Aedes aegypti cells cultures [34]. 325 
These findings are strongly suggestive of a modulation over the viral load and the immune response 326 
carried out by concurrent Gram-negative coinfections during dengue, they seem to agree with the 327 
previously cited study reporting a correlation between dengue severity and LPS plasma levels [28] 328 
and if they were confirmed in human models, we could even expect that in Gram-negative 329 
coinfections sings and symptoms related to DEV active replication could temporarily worsen or be 330 
prolonged right after the beginning of the antibiotic therapy because of the release of a large amount 331 
of LPS from killed bacteria.  332 
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We are clearly far from understanding the physiopathology of CB and BC in dengue, but certainly 333 
we can note that there is a mutual life-threatening strengthening influence between DEV and 334 
bacteria.  335 
Conclusion 336 
A significant portion of dengue cases could be associated to a bacterial infection, but the real 337 
burden of this emerging concern is still not computable accurately due to the lack of a shared 338 
approach to the study of this issue and of a surveillance system monitoring and reporting 339 
systematically the dual infections, also in western countries. Clinicians need a greater awareness 340 
about CB and BC in dengue since that in addition to be potentially more serious and with a higher 341 
risk of complications, dual infections can put clinicians in front of management problems and can 342 
predispose to delays in the diagnosis and in the beginning of the most appropriate therapy, able to 343 
prevent aggravation in mortality and morbidity. We encourage clinicians to suspect CB and BC in 344 
any DEV case, especially in patients with comorbidities, elderly, with a long lasting fever or more 345 
severe forms of dengue. In such cases, the DDIS and the procalcitonin may prove useful diagnostic 346 
tools, if their high specificity and sensitivity respectively will be confirmed by further studies [8, 347 
18]. Moreover, not to prescribe unnecessary antibiotics because of false positive results, when it is 348 
possible, we recommend to prefer biological sample culture tests over serology to confirm a 349 
suspicion of bacterial coinfection in dengue, considering yet that some of the involved 350 
microorganisms could be difficult to culture. Nevertheless, we do not recommend the indiscriminate 351 
use of biological sample cultures nor the administration of an empiric antibiotic treatment to each 352 
suspected or confirmed DEV case, since that the former would result in a huge waste of human and 353 
economic resources, especially in developing countries and the latter may lead to the selection of 354 
multiresistant bacteria. Evaluating the risk factors, the laboratory, the clinical presentation and its 355 
evolution, clinicians should be able to identify DEV-infected patients in need of appropriate further 356 
diagnostic investigations and of an empiric antibiotic therapy to reduce mortality and morbidity. 357 
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Fig. 1 The hypothesized mechanisms whereby Dengue Virus may induce Concurrent Bacteremia and 359 
Bacterial Coinfections 360 
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Table 1. Main features of the three published studies focused on Concurrent Bacteremia in Dengue 451 
 Lee IK et al, Am J Trop Med 
Hyg 2005 
See KC et al, Am J Trop Med 
Hyg 2013 
Thein TL et al, 
J Microbiol Immunol Infect 
2015 
Study 
population 
100 2065 9553 
Study design Retrospective  Retrospective  Retrospective 
Age >18 years >16 years >18 years 
Female 46 (46%) 860 (42%) NA 
Country Taiwan Singapore Singapore 
DEV cases DHF or DSS All types All types 
CB 7 (7%) 25 (1,2%) 18 (0,18%) 
BC NA 83 (4%) 29 (0,3%) 
Fatality rate 2/7 (28,5%) 16/83 (19,3%) 3/18 (16,7%) 
Source of 
Bacteremia 
1 Meningitis 
1 Facial cellulitis 
5 Primary bacteremia 
3 Endocarditis 
2 Vascular infections 
1 Limb cellulitis 
6 Bile ducts infections 
4 UTI 
9 Primary bacteremia 
NA 
Isolated 
Pathogens 
3 Klebsiella pneumoniae 
1 Klebsiella ozaenae 
1 Rosemonas spp  
1 Moraxella lacunata 
1 Enterococcus faecalis 
8 Staphylococcus aureus  
(5 MSSA and 3 MRSA) 
6 Escherichia coli 
4 Klebsiella pneumoniae 
2 Salmonella typhi 
1 Salmonella enteritidis 
1 Streptococcus agalactiae 
1 Group A streptococcus 
1 Aeromonas maltophilia 
1 Kluyvera cryocrescens 
5 Staphylococcus aureus 
4 Salmonella typhi 
3 Escherichia coli 
2 Klebsiella pneumoniae 
2 Streptococcus spp 
1 Pseudomonas aeruginosa 
1 Unspecified anaerobe 
19 
 
CB Diagnosis Any positive blood culture 
within 72 hours of admission 
for DEV 
Any positive blood culture 
within 48 hours of admission 
for DEV or 
Any clinical diagnosis 
Any positive blood culture 
within 72 hours of admission 
for DEV 
Blood Culture 
testing Criteria 
NA NA Patients presenting clinical 
deterioration despite DEV 
treatment 
DEV 
Diagnosis 
PCR, IgM capture ELISA or 
fourfold increase of HIT 
PCR, IgM ELISA or NS1 
antigen 
RT-PCR or Rapid Dengue 
Duo Strip Test 
Exclusion 
Criteria 
Prior antibiotic treatment 
Contamination of cultures 
Contamination of cultures NA 
Legend: DHF Dengue Hemorragic Fever; DSS Dengue Shock Syndrome; CB Concurrent Bacteremia; BC Bacterial 452 
Coinfections including also CB; NA Not Available for missing or unspecified data; UTI Urinary Tract Infections; 453 
MSSA Methicillin-Sensitive Staphylococcus aureus; MRSA Methicillin-Resistant Staphylococcus aureus; HIT 454 
Hemagglutination inhibition titers; RT-PCR Reverse Transcriptase-Polymerase Chain Reaction. 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
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Table 2. Bacterial Coinfections and Concurrent Bacteremia in Dengue: case reports from literature 466 
Age & 
Sex 
Associated Bacteria Diagnostic tests Possible 
DB 
Outcome Reference 
NA Salmonella typhi NA No Recovery Bansal R et al, 
Trop Doct 2015 
10 F Leptospira spp DEV and Leptospira IgM 
serology 
Yes Recovery Nunez-Garbin A 
et al, Rev Peru 
Med Exp Salud 
Publica 2015 
52 M Leptospira spp DEV and Leptospira serology Yes Death Wijesinghe A et 
al, BMC Res 
Notes 2015 
10 M Salmonella typhi Blood cultures for S typhi, 
DEV NS1 and IgM ELISA 
No Recovery 6 
22, 64, 
67 M 
Leptospira spp Leptospira spp antigen, IHC 
and PCR on autoptic samples, 
DEV RT-PCR 
No Death 4 
25 F Orientia 
tsutsugamushi 
Weil-Felix and PCR for O 
tsutsugamushi, DEV NS1 and 
IgM  
No Recovery Kumar S et al, J 
Vector Borne Dis 
2014 
30 F Stenotrophomonas 
maltophilia 
Blood culture for S 
maltophilia, DEV NS1 antigen 
No Recovery Sriranaraj S et al, 
Australas Med J 
2014 
48 F Enterococcus 
faecium 
Blood cultures for E faecium, 
DEV IgG serology 
Yes Death Tsai JJ et al, 
Southeast Asian J 
Trop Med Public 
Health 2013 
24 M Salmonella typhi Blood cultures for S typhi, 
DEV NS1 and serology 
No Recovery Vaddadi S et al, 
Int J Res Dev 
Health 2013 
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17 M MRSA Blood culture for MRSA, DEV 
IgM ELISA 
Yes Death Sunderalingam V 
et al, Case Rep 
Infect Dis 2013 
42 M Leptospira spp Leptospira spp antigen IHC on 
kidney autoptic samples, DEV 
NS1 on blood 
No Death Sharp TM et al, 
Emerg Infect Dis 
2012 
46 NA Leptospira spp NA No  NA Cadelis G, Rev 
Pneumol Clin 
2012 
40 F Orientia 
tsutsugamushi 
Weil-Felix and IgM for O 
tsutsugamushi, DEV IgM 
Yes Recovery Iqbal N et al, Trop 
Med Health 2012 
15 M Staphylococcus 
aureus 
Sputum cultures for S aureus, 
DEV ELISA serology 
Yes Recovery Nagassar RP et al, 
BMJ Case Rep 
2012 
28 M Burkholderia 
pseudomallei 
Ascitic fluid culture for B 
pseudomallei, DEV PCR on 
autoptic samples 
No  Death Macedo RN et al, 
Rev Soc Bras 
Med Trop 2012 
14 M Staphylococcus 
aureus 
Autoptic samples cultures for 
S aureus, DEV IHC on 
autoptic samples 
No Death Araujo SA et al, 
Am J Trop Med 
Hyg 2010 
23 M Brucella melitensis Blood culture for B melitensis, 
DEV serology 
Yes Recovery 26 
23 M Leptospira spp Leptospira and DEV IgM 
ELISA 
Yes Recovery Behera B et al, J 
Infect Dev Ctries 
2009 
36, 39, 
39, 42, 
43 M 
Staphylococcus 
aureus 
Blood, intraoperative and 
wound specimens cultures for 
S aureus, DEV PCR on serum 
No Recovery 5 
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6 F Streptococcus 
pyogenes 
Blood cultures for S pyogenes, 
DEV serology 
Yes Recovery Vitug MR et al, 
Int J Dermatol 
2006 
8 F Mycoplasma 
pneumoniae 
Mycoplasma agglutination 
test, DEV IgM rapid test, RT-
PCR and hemoagglutination 
test 
Yes Recovery Likitnukul S et al, 
Southeast Asian J 
Trop Med Public 
Health 2004 
6, 9 F, 
9, 11 M 
Salmonella typhi 
Salmonella paratyphi 
Blood cultures for Salmonella 
spp, DEV IgM rapid test and 
hemagglutination test 
Yes Recovery Basuki PS, Folia 
Med Indon 2003 
44 F Shigella sonnei Stool culture for S sonnei, 
DEV IgM rapid test and Duo 
IgM IgG-capture ELISA 
Yes  Recovery Charrel RN et al, 
Emerg Infect Dis 
2003 
NA Leptospira spp NA No NA Kaur H et al, 
Indian J 
Gastroenterol 
2002 
2 F Leptospira spp Leptospira and DEV IgM 
ELISA 
Yes Recovery Rele MC et al, 
Indian J Med 
Microbiol 2001 
19 F, 
32 M 
Salmonella typhi Blood cultures for S typhi, 
DEV serology 
No  Recovery Sudjana P et al, 
Southeast Asian 
J Trop Med 
Public Health 
1998 
Legend: DB Diagnostic Bias; DEV Dengue virus; NA Data Not Available; IHC Immunohistochemistry; MRSA 467 
Methicillin-resistant Staphylococcus aureus; RT-PCR Reverse-Transcriptase Polymerase Chain Reaction. 468 
 469 
 470 
 471 
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Figure 1 The hypothesized mechanisms whereby dengue virus may induce concurrent bacteremia 472 
and bacterial coinfections 473 
 474 
